MARKET

OVID

OVID

Ovid
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.120
-0.110
-3.41%
After Hours: 3.140 +0.02 +0.64% 17:41 02/27 EST
OPEN
3.110
PREV CLOSE
3.230
HIGH
3.330
LOW
3.015
VOLUME
502.57K
TURNOVER
--
52 WEEK HIGH
5.24
52 WEEK LOW
1.530
MARKET CAP
149.19M
P/E (TTM)
-1.7852
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of OVID and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average OVID stock price target is 13.00 with a high estimate of 20.00 and a low estimate of 8.00.

EPS

OVID News

More
  • Ovid Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference
  • GlobeNewswire · 2d ago
  • Gilead, Bristol-Myers Pumped More Into R&D Than Shareholder Enrichments
  • GuruFocus.com · 01/23 23:00
  • Pharma Company Buybacks: Do They Really Benefit Shareholders?
  • GuruFocus.com · 01/21 22:09
  • Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Invest In Growth?
  • Simply Wall St. · 01/10 16:43

Industry

Biotechnology & Medical Research
-2.24%
Pharmaceuticals & Medical Research
-2.52%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About OVID

Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. Ovid has initiated the Phase II STARS trial of OV101 in adults with Angelman syndrome and a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.
More

Webull offers kinds of Ovid Therapeutics Inc stock information, including NASDAQ:OVID real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OVID stock news, and many more online research tools to help you make informed decisions.